Advarra purchases IRBco

By Jenni Spinner contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: acquisition, advarra, Irb

The institutional review board and research technology solutions provider has acquired IRBco to expand its reach and presence in North America.

Advarra—which provides institutional review board (IRB), institutional biosafety committee, research technology solutions, and quality/compliance consulting services—has purchased IRB Company (IRBco). IRBco is an AAHRPP-accredited central IRB in operation since 1981.

According to Gadi Saarony, Advarra CEO, the acquisition will enable his company to further its mission to empower clinical trials to do their work, and to advance human health.

IRBco studies will be fully integrated with Advarra in a matter of weeks, and we look forward to the additional talent and board expertise this will bring to our organization​,” he said. “We will maintain our focus on developing altogether better capabilities that serve clients and protect research participants​.”

Advarra offers a range of products and services designed to streamline processes, create efficiencies, and support research compliance. These capabilities are intended to provide the research and biopharmaceutical industries with integrated solutions.

According to Advarra, the acquisition will increase its reach to more than 3,200 research institutions, hospital systems, and academic medical centers.

Anil Sharma, CEO of IRBco, said joining forces makes sense for both companies, and their clients.

Joining the Advarra family is an ideal fit​,” he said. “We are pleased to offer our mutual customers expanded resources—innovations, efficiencies, and all the characteristics to collaboratively complement moving research forward​.”

Overall, Advarra offers technology products and consulting services that are geared toward accelerating research through technologies, strategic partnerships, and customer-centric service. According to the company, the approach reduces operational costs, streamlines study startup activities, prevents errors and administrative burdens, and saves time for clinical research sponsors, CROs, investigators, and institutions.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars